Archive
2021, Volume 9
2020, Volume 8
2019, Volume 7
2018, Volume 6
2017, Volume 5
2016, Volume 4
2015, Volume 3
2014, Volume 2
2013, Volume 1
Special Issues
Prospects for the Treatment of Endometriosis: The Effect of Immune Peptides on the Reactivation of Immune Surveillance over Ectopic Endometrial Cells
Journal of Gynecology and Obstetrics
Volume 8, Issue 5, September 2020, Pages: 148-153
Received: Sep. 13, 2020; Accepted: Sep. 29, 2020; Published: Oct. 13, 2020
Volume 8, Issue 5, September 2020, Pages: 148-153
Received: Sep. 13, 2020; Accepted: Sep. 29, 2020; Published: Oct. 13, 2020
Views 167 Downloads 93
Authors
Natalia Zakharenko, Endocrine Gynecology Department, NAMS Ukraine Institute of Pediatrics, Obstetrics and Gynecology, Kyiv, Ukraine
Oleksii Tatskiy, Department of Research and Development, International Biotherapy Institute, Kyiv, Ukraine
Sergii Konovalenko, Department of Research and Development, International Biotherapy Institute, Kyiv, Ukraine
Abstract
Background. Genital endometriosis (GE) remains a significantly common disease, occurring in 0.5-5% of fertile women and in 25-40% of women with infertility. In patients with GE, there is a decrease in apoptosis in endometrial cells compared to healthy women, even more pronounced in ectopic foci, as a result of which their proliferative activity increases and the ability to abnormal implantation increases. Objective. Our task was to study the patterns of interaction of immune cells with ectopic endometrial cells, as well as to determine the molecular biological levers of influence on immune surveillance in endometriosis. Given the ability of ectopic cells to change the microenvironment in their favor, we aimed to find an effective tool to restore immune surveillance of endometrioma and thus offer a promising treatment for the disease. Method. For the purpose of writing this review article, we used the method of selection and analysis of scientific publications with open access. Results. The use of immune peptides in endometriosis, which are capable of activating regulatory macrophages and stimulating the recruitment of T-lymphocytes, opens up new possibilities for controlling the disease. Arecur, which contains immune peptides, including defensins and RJP-1, tunes immune cells to maximize their productivity against ectopic tissue, potentially creating conditions for the prevention of endometriosis-associated ovarian cancer. Conclusion. The use of immune peptides in endometriosis quite predictably contributes to more efficient work of local immunity. Immune cells potentiated with peptides not only independently attack and separate the intercellular connections in the endometrioma, but also provoke apoptosis of ectopic cells. The use of immune peptides in endometriosis opens up new prospects for increasing the effectiveness of treatment and prevention of this disease.
Keywords
Endometriosis, Ectopic Cells, Immune Surveillance, Immune Peptides, Arecur
To cite this article
Natalia Zakharenko,
Oleksii Tatskiy,
Sergii Konovalenko,
Prospects for the Treatment of Endometriosis: The Effect of Immune Peptides on the Reactivation of Immune Surveillance over Ectopic Endometrial Cells, Journal of Gynecology and Obstetrics.
Vol. 8, No. 5,
2020, pp. 148-153.
doi: 10.11648/j.jgo.20200805.14
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Zakharenko N. F., Modern vision of immunological aspects of endometriosis. Women's health. 2012; №9 (75): 121-123.
[2]
Ball E, Khan KS. Recent advances in understanding and managing chronic pelvic pain in women with special consideration to endometriosis. F1000Res. 2020; 9: F1000 Faculty Rev-83.
[3]
Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, Diagnosis and Clinical Management. Curr Obstet Gynecol Rep. 2017; 6 (1): 34-41.
[4]
Wang Y, Nicholes K, Shih IM. The Origin and Pathogenesis of Endometriosis. Annu Rev Pathol. 2020; 15: 71-95.
[5]
Rolla E. Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment. F1000Res. 2019; 8: F1000 Faculty Rev-529.
[6]
Sieberg CB, Lunde CE, Borsook D. Endometriosis and pain in the adolescent- striking early to limit suffering: A narrative review. Neurosci Biobehav Rev. 2020; 108: 866-876.
[7]
Tsonis O, Barmpalia Z, Gkrozou F, et al. Endometriosis in adolescence: Early manifestation of the traditional disease or a unique variant?. Eur J Obstet Gynecol Reprod Biol. 2020; 247: 238-243.
[8]
Su KM, Wang PH, Yu MH, Chang CM, Chang CC. The recent progress and therapy in endometriosis-associated ovarian cancer. J Chin Med Assoc. 2020; 83 (3): 227-232.
[9]
Trapero, C.; Vidal, A.; Fernández-Montolí, M. E.; Coroleu, B.; Tresserra, F.; Barri, P.; Gómez de Aranda, I.; Sévigny, J.; Ponce, J.; Matias-Guiu, X.; Martín-Satué, M. Impaired Expression of Ectonucleotidases in Ectopic and Eutopic Endometrial Tissue Is in Favor of ATP Accumulation in the Tissue Microenvironment in Endometriosis. Int. J. Mol. Sci. 2019, 20, 5532.
[10]
Leonardi M, Horne AW, Vincent K, et al. Self-management strategies to consider to combat endometriosis symptoms during the COVID-19 pandemic. Hum Reprod Open. 2020; 2020 (2): hoaa028.
[11]
Liu Y, Zhang Z, Yang F, et al. The role of endometrial stem cells in the pathogenesis of endometriosis and their application to its early diagnosis. Biol Reprod. 2020; 102 (6): 1153-1159.
[12]
Hogg C, Horne AW, Greaves E. Endometriosis-Associated Macrophages: Origin, Phenotype, and Function. Front Endocrinol (Lausanne). 2020; 11: 7.
[13]
García-Gómez E, Vázquez-Martínez ER, Reyes-Mayoral C, Cruz-Orozco OP, Camacho-Arroyo I, Cerbón M. Regulation of Inflammation Pathways and Inflammasome by Sex Steroid Hormones in Endometriosis. Front Endocrinol (Lausanne). 2020; 10: 935.
[14]
Zhao Y, Gong P, Chen Y, et al. Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. Sci Transl Med. 2015; 7 (271): 271ra9.
[15]
Han SJ, Hawkins SM, Begum K, Jung SY, Kovanci E, Qin J, Lydon JP, DeMayo FJ, O’Malley BW. A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis. Nat Med. 2012; 18: 1102–1111.
[16]
Han S. J., O’Malley B. W. The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis. Hum Reprod Update. 2014 Jul; 20 (4): 467–484.
[17]
Li R, Qiu Y. Diagnostic value of serum ICAM-1 for endometriosis: A meta-analysis. Medicine (Baltimore). 2018; 97 (31): e11760.
[18]
Sikora J., Smycz-Kubanska M., Mielczarek-Palacz A., Kondera-Anasz Z., Abnormal peritoneal regulation of chemokine activation-The role of IL-8 in pathogenesis of endometriosis. Am. J. Reprod. Immunol. 2017; 77.
[19]
Garcia Velasco J. A., Arici A. Elevated soluble Fas ligand levels may suggest a role for apoptosis in women with endometriosis // Fertil. Steril. 2002. – Vol. 78. – P. 855–859.
[20]
Delbandi, A., Mahmoudi, M., Shervin, A. et al. Evaluation of apoptosis and angiogenesis in ectopic and eutopic stromal cells of patients with endometriosis compared to non-endometriotic controls. BMC Women's Health 20, 3 (2020).
[21]
Vercellini P, Buggio L, Berlanda N, Barbara G, Somigliana E, Bosari S. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril. 2016; 106 (7): 1552–1571. e2.
[22]
Wang S, Qiu L, Lang JH, Shen K, Huang HF, Pan LY, Wu M, Yang JX, Guo LN. Prognostic analysis of endometrioid epithelial ovarian cancer with or without endometriosis: a 12-year cohort study of Chinese patients. American journal of obstetrics and gynecology. 2013; 209 (3): 241–e241-249.
[23]
Wolthuis AM, Meuleman C, Tomassetti C, D’Hooghe T, de Buck van Overstraeten A, D’Hoore A. Bowel endometriosis: colorectal surgeon’s perspective in a multidisciplinary surgical team. World J Gastroenterol. 2014; 20 (42): 15616–15623.
[24]
Wu MH, Shoji Y, Chuang PC, Tsai SJ. Endometriosis: disease pathophysiology and the role of prostaglandins. Expert Rev Mol Med. 2007; 9 (2): 1–20.
[25]
Hansen KE, Kesmodel US, Kold M, Forman A. Long-term effects of mind fulness-based psychological intervention for coping with pain in endometriosis: a six-year follow-up on a pilot study. Nord Psychol. 2017; 69 (2): 100-109.
[26]
Jiang L, Yan Y, Liu Z, Wang Y. Inflammation and endometriosis. Front Biosci. 2016; 21: 941–948.
[27]
Working group of ESGE, ESHRE, and WES, Keckstein J, Becker CM, et al. Recommendations for the surgical treatment of endometriosis. Part 2: deep endometriosis. Hum Reprod Open. 2020; 2020 (1): hoaa002.
[28]
Habib N, Centini G, Lazzeri L, et al. Bowel Endometriosis: Current Perspectives on Diagnosis and Treatment. Int J Womens Health. 2020; 12: 35-47.
[29]
Leonardi M, Hicks C, El-Assaad F, El-Omar E, Condous G. Endometriosis and the microbiome: a systematic review. BJOG. 2020; 127 (2): 239-249.
[30]
Lin YH, Chen YH, Chang HY, Au HK, Tzeng CR, Huang YH. Chronic Niche Inflammation in Endometriosis-Associated Infertility: Current Understanding and Future Therapeutic Strategies. Int J Mol Sci. 2018; 19 (8): 2385.
[31]
Divyashree M, Mani MK, Reddy D, et al. Clinical Applications of Antimicrobial Peptides (AMPs): Where do we Stand Now? Protein Pept Lett. 2020; 27 (2): 120-134.
[32]
Lazzaro BP, Zasloff M, Rolff J. Antimicrobial peptides: Application informed by evolution. Science. 2020; 368 (6490): eaau5480.
[33]
Shypulin V, Stoliarova O, Konovalenko V, Tatskyy O, Didenko G, Konovalenko S. Study of the Exogenous Peptide Effect on the TGF-β1 Expression-A Risk Factor for the Hepatocellular Carcinoma Recurrence. American Journal of Biomedical and Life Sciences. Vol. 7, No. 4, 2019, pp. 73-78.
[34]
Litvinenko O. O, Tatskiy O. F, Konovalenko V. F, et al. Breast Cancer Relapse Prevention: Role of Anti-Relapsing Immunocorrection. Cancer Sci Res. 2019; 2 (2); 1-6.
[35]
Vercellini P. Introduction Management of endometriosis: moving toward a problem-oriented and patient-centered approach. Fertil Steril. 2015; 104 (4): 761–763.
[36]
Malvezzi H, Marengo EB, Podgaec S, Piccinato CA. Endometriosis: current challenges in modeling a multifactorial disease of unknown etiology. J Transl Med. 2020; 18 (1): 311.
[37]
Beniuk V, Goncharenko V, Kurchenko A, Tatskyy O, Konovalenko S, Vintoniuk S, Melnikov S, Nurimanov K, Podpriatov S. Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology. International Journal of Immunology. Vol. 8, No. 1, 2020, pp. 1-8.
PUBLICATION SERVICES
JOIN US
SPECIAL SERVICES
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186
FOLLOW SciencePG
